Saturday, September 23, 2023
Saturday, September 23, 2023

Conformis Reports New Clinical Study Finds Bilateral Knee Conformis Reports Patients Prefer Conformis’ Fully Personalized Solution Over Competitive Off-the-Shelf Implants by a Factor of Over 10 to 1

Conformis, Inc. (NASDAQ:CFMS), the pioneer and leader of fully personalized orthopedic medical devices, today announced results of a published retrospective study of patients showing the superiority of Conformis’ implants in several key measures of clinical success and patient satisfaction.

According to the study published in The Journal of Bone & Joint Surgery Reviews (JBJS Reviews)1, patients who had undergone bilateral total knee arthroplasty (TKA) preferred their Conformis fully personalized knee compared to their bilateral off-the-shelf knee at a rate of more than 10 to 1.

The study surveyed 47 TKA patients who had a fully personalized Conformis implant in one knee after previously receiving a competitive off-the-shelf implant in their other knee. The study found that 72.3 percent of the patients studied preferred their fully personalized Conformis knee replacement, compared to 6.4 percent of patients who preferred their traditional off-the-shelf (OTS) implant. The remaining 21.3 percent reported no perceived difference between the two knee implants.

Conformis notes the study, believed to be the first ever to directly examine patient-reported outcomes comparing fully personalized and traditional off-the-shelf implants in the same patient as a control, underscores the higher levels of satisfaction and lower levels of pain and joint awareness associated with fully personalized implants. The patients reported less pain, better perceived mobility and a more “normal” feeling in the fully personalized Conformis implant.

“This study confirms what the surgeons and engineers working at Conformis have known from the beginning: a fully personalized knee replacement that is designed specifically for each patient’s unique anatomy and original motion clearly contributes to better clinical outcomes and happier patients,” said Mark Augusti, Chief Executive Officer and President of Conformis.

He added, “Our fully personalized knee system has demonstrated its clinical benefits in dozens of peer-reviewed studies over the years, and this patient self-controlled research further validates that the patients who are living with two different knee implants can feel the difference. Simply put, our fully personalized implants fit better and feel more natural.”

The patients in the study were evaluated using the well-established Knee Injury and Osteoarthritis Outcome Score, Joint Replacement (KOOS, JR), the Forgotten Joint Score (FJS) and preference questionnaire methodologies. “New technological advances in the past decades have fueled the race for the ‘happiest patient’ following total knee arthroplasty,” wrote the authors. “Patients in this study with bilateral knee joint replacement showed an overall preference for customized total knee arthroplasty.”

“Participants in the present study overall favored the custom total knee arthroplasty (C-TKA) over the standard prostheses in all surveyed categories: pain, motion, stability, ‘normal’ feel, and overall preference,” noted the authors. “On the basis of these findings, the combination of more precise implant fit and component rotation of C-TKA compared with OTS TKA may have been a contributing factor for lower pain levels and functional superiority, thus contributing to patients’ preference for customized over OTS TKA.”

Conformis has been a leader in patient specific technology since its founding in 2004. The company continues to innovate. Most recently, Conformis launched the Image-to-Implant® Platinum Services℠Program (PSP), the first deluxe personalization upgrade services program in the orthopedic market.


1. Schroeder, Lennart MD1,a; Dunaway, Andrew DO2; Dunaway, Daniel MD3 A Comparison of Clinical Outcomes and Implant Preference of Patients with Bilateral TKA, JBJS Reviews: February 2022 – Volume 10 – Issue 2 – e20.00182 doi: 10.2106/JBJS.RVW.20.00182

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures. Receives FDA Clearance and Breakthrough Device Designation has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy